Jane Street’s Xenetic Biosciences XBIO Stock Holding History

Jane Street’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,977	Closed	-$11.3K	–	10051
2022 Q4	$11.3K	Buy	+3,977	New	+$17.5K	﹤0.01%	8743

Other funds holding XBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street's XBIO Position: Q1 2023 in Review

Jane Street sold out of Xenetic Biosciences (XBIO) in Q1 2023, closing a stake of 3,977 shares — an estimated $11.3K sold.

Jane Street first reported a position in XBIO in Q4 2022 and held it in 1 quarter. The position peaked at $11.3K in Q4 2022. 19 funds tracked by Wall St. Rank hold XBIO as of Q1 2023.

Jane Street reported no remaining Xenetic Biosciences position as of Q1 2023 after selling out during the quarter.
Jane Street sold 3,977 Xenetic Biosciences shares in Q1 2023, an estimated $11.3K.
Jane Street first reported a position in Xenetic Biosciences in Q4 2022 and held it in 1 quarter.
Jane Street's Xenetic Biosciences position peaked at $11.3K in Q4 2022.
19 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q1 2023.

Based on Jane Street's 13F filing for Q1 2023, filed 16 May 2023.